- Home
- RIV vs MNPR Comparison
RIV vs MNPR Comparison
Compare RIV & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIV
- MNPR
- Stock Information
- Founded
- RIV 2015
- MNPR 2014
- Country
- RIV United States
- MNPR United States
- Employees
- RIV N/A
- MNPR N/A
- Industry
- RIV Finance Companies
- MNPR Biotechnology: Pharmaceutical Preparations
- Sector
- RIV Finance
- MNPR Health Care
- Exchange
- RIV Nasdaq
- MNPR Nasdaq
- Market Cap
- RIV 266.0M
- MNPR 248.8M
- IPO Year
- RIV N/A
- MNPR 2019
- Fundamental
- Price
- RIV $12.16
- MNPR $57.00
- Analyst Decision
- RIV
- MNPR Strong Buy
- Analyst Count
- RIV 0
- MNPR 11
- Target Price
- RIV N/A
- MNPR $68.60
- AVG Volume (30 Days)
- RIV 87.6K
- MNPR 41.0K
- Earning Date
- RIV 01-01-0001
- MNPR 11-07-2025
- Dividend Yield
- RIV 12.85%
- MNPR N/A
- EPS Growth
- RIV N/A
- MNPR N/A
- EPS
- RIV N/A
- MNPR N/A
- Revenue
- RIV N/A
- MNPR N/A
- Revenue This Year
- RIV N/A
- MNPR N/A
- Revenue Next Year
- RIV N/A
- MNPR N/A
- P/E Ratio
- RIV N/A
- MNPR N/A
- Revenue Growth
- RIV N/A
- MNPR N/A
- 52 Week Low
- RIV $9.63
- MNPR $3.65
- 52 Week High
- RIV $12.43
- MNPR $58.77
- Technical
- Relative Strength Index (RSI)
- RIV 52.02
- MNPR 74.23
- Support Level
- RIV N/A
- MNPR $42.51
- Resistance Level
- RIV $12.24
- MNPR $45.78
- Average True Range (ATR)
- RIV 0.11
- MNPR 3.78
- MACD
- RIV -0.44
- MNPR 2.28
- Stochastic Oscillator
- RIV 98.38
- MNPR 92.79
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.